Brain

Masimo and Denon Introduce White PerL™ and PerL Pro™ Earbuds, Redefining Style and Customization in Personalized Audio

The only earbuds on the market that analyze your hearing profile to generate truly custom sound made just for youIRVINE,…

2 months ago

FSD Pharma Provides Update on Celly Nu’s New Packaging for unbuzzd(TM)

TORONTO, ON / ACCESSWIRE / May 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update by way…

2 months ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025Company committed to addressing…

2 months ago

Glioblastoma Foundation(R) Announces the Establishment of Groundbreaking Genomic Testing & Research Laboratory

DURHAM, NC / ACCESSWIRE / May 15, 2024 / The Glioblastoma Foundation announced today the establishment of a pioneering Genomic…

2 months ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical…

2 months ago

Eli Lilly’s and AstraZeneca’s Former Head of Research Dr. Jan Lundberg Elected as a New Board Member

STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops…

2 months ago

Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2024

STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) Today, 14 May 2024, the annual general meeting…

2 months ago

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic…

2 months ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data…

2 months ago

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to…

2 months ago